[HTML] frontiersin.org

[HTML][HTML] A perspective on oligonucleotide therapy: Approaches to patient customization

S Thakur, A Sinhari, P Jain, HR Jadhav - Frontiers in Pharmacology, 2022 - frontiersin.org
It is estimated that the human genome encodes 15% of proteins that are considered to be
disease-modifying. Only 2% of these proteins possess a druggable site that the approved …
被引用次数：83 相关文章

A perspective on oligonucleotide therapy: Approaches to patient customization

S Thakur, A Sinhari, P Jain, H Jadhav - Frontiers in Pharmacology, 2022 - europepmc.org
It is estimated that the human genome encodes 15% of proteins that are considered to be
disease-modifying. Only 2% of these proteins possess a druggable site that the approved …

A perspective on oligonucleotide therapy: Approaches to patient customization

S Thakur, A Sinhari, P Jain… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
It is estimated that the human genome encodes 15% of proteins that are considered to be
disease-modifying. Only 2% of these proteins possess a druggable site that the approved …
[HTML] nih.gov

[HTML][HTML] A perspective on oligonucleotide therapy: Approaches to patient customization

S Thakur, A Sinhari, P Jain… - Frontiers in Pharmacology, 2022 - ncbi.nlm.nih.gov
It is estimated that the human genome encodes 15% of proteins that are considered to be
disease-modifying. Only 2% of these proteins possess a druggable site that the approved …

A perspective on oligonucleotide therapy: Approaches to patient customization.

S Thakur, A Sinhari, P Jain, HR Jadhav - Frontiers in Pharmacology, 2022 - europepmc.org
It is estimated that the human genome encodes 15% of proteins that are considered to be
disease-modifying. Only 2% of these proteins possess a druggable site that the approved …